Technical Analysis for ONCR - Oncorus, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Flat |
| Historical ONCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 2.01% | |
| Boomer Sell Setup | Bearish Swing Setup | -3.11% | |
| Narrow Range Bar | Range Contraction | -3.11% | |
| NR7 | Range Contraction | -3.11% | |
| NR7-2 | Range Contraction | -3.11% | |
| Inside Day | Range Contraction | -3.11% | |
| Wide Bands | Range Expansion | -3.11% | |
| NR7 | Range Contraction | -3.72% | |
| Inside Day | Range Contraction | -3.72% | |
| Wide Bands | Range Expansion | -3.72% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 3 hours ago |
| Rose Above Previous Day's High | about 5 hours ago |
| Rose Above 10 DMA | about 5 hours ago |
| 20 DMA Resistance | about 5 hours ago |
| Up 5% | about 5 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Oncolytics Biotech Brain Cancer Herpes Simplex Herpes Simplex Virus Pelareorep Oncolytic Virus
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Oncolytics Biotech Brain Cancer Herpes Simplex Herpes Simplex Virus Pelareorep Oncolytic Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.8603 |
| 52 Week Low | 11.5 |
| Average Volume | 203,980 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 16.77 |
| 20-Day Moving Average | 14.31 |
| 10-Day Moving Average | 13.71 |
| Average True Range | 1.18 |
| ADX | 31.13 |
| +DI | 15.76 |
| -DI | 25.68 |
| Chandelier Exit (Long, 3 ATRs ) | 13.70 |
| Chandelier Exit (Short, 3 ATRs ) | 15.05 |
| Upper Bollinger Band | 16.93 |
| Lower Bollinger Band | 11.70 |
| Percent B (%b) | 0.33 |
| BandWidth | 36.52 |
| MACD Line | -0.85 |
| MACD Signal Line | -1.11 |
| MACD Histogram | 0.2523 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 14.88 | ||||
| Resistance 3 (R3) | 14.99 | 14.62 | 14.64 | ||
| Resistance 2 (R2) | 14.62 | 14.25 | 14.56 | 14.56 | |
| Resistance 1 (R1) | 14.03 | 14.03 | 13.85 | 13.93 | 14.48 |
| Pivot Point | 13.66 | 13.66 | 13.57 | 13.61 | 13.66 |
| Support 1 (S1) | 13.08 | 13.30 | 12.89 | 12.97 | 12.42 |
| Support 2 (S2) | 12.71 | 13.07 | 12.65 | 12.34 | |
| Support 3 (S3) | 12.12 | 12.71 | 12.26 | ||
| Support 4 (S4) | 12.02 |
